Cargando…

Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report

RET-rearranged fusions have been considered as oncogenic drivers in 1% to 2% of non-small cell lung cancers (NSCLC). ARROW study has demonstrated a new selective RET tyrosine kinase inhibitors (TKIs) shows remarkable and durable responses in RET-rearranged NCSLC. In this study mainly recruited patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Linping, Ji, Wenxiang, Xu, Yunhua, Han, Yuchen, Jian, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704906/ https://www.ncbi.nlm.nih.gov/pubmed/36451418 http://dx.doi.org/10.1097/MD.0000000000031480

Ejemplares similares

Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report
por: Meng, Yan, et al.
Publicado: (2022)

Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation
por: Zhao, Jing, et al.
Publicado: (2023)

EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells
por: Chang, Hyun, et al.
Publicado: (2017)

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
por: Hescot, Ségolène, et al.
Publicado: (2022)

Pralsetinib treatment for multiple RET fusions in lung adenocarcinoma: a case report
por: Cao, Xiangming, et al.
Publicado: (2022)

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report
por: Zhao, Zichen, et al.
Publicado: (2022)

Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC
por: An, Li, et al.
Publicado: (2022)

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
por: d'Arienzo, Paolo D., et al.
Publicado: (2023)

Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET–rearranged thyroid cancer
por: Raman, Renuka, et al.
Publicado: (2022)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
por: Gao, Ming, et al.
Publicado: (2023)

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
por: Wang, Sha-Sha, et al.
Publicado: (2022)

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
por: Zhou, Ning, et al.
Publicado: (2022)

RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
por: Zhang, Tongyi, et al.
Publicado: (2023)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
por: Wang, Sha-Sha, et al.
Publicado: (2022)

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
por: Lu, Chang, et al.
Publicado: (2022)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization
por: Schmutzler, Brian S, et al.
Publicado: (2011)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
por: Shen, Tao, et al.
Publicado: (2021)

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
por: Ortiz, Michael V., et al.
Publicado: (2020)

Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report
por: Wu, Ying, et al.
Publicado: (2022)

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers
por: Adashek, Jacob J., et al.
Publicado: (2021)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
por: Nannini, Margherita, et al.
Publicado: (2022)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

The RET gene encodes RET protein, which triggers intracellular signaling pathways for enteric neurogenesis, and RET mutation results in Hirschsprung's disease
por: Bhattarai, Chacchu, et al.
Publicado: (2022)

A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report
por: Qin, Hao, et al.
Publicado: (2023)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
por: Osta, Badi El, et al.
Publicado: (2020)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research
por: Meng, Yan, et al.
Publicado: (2022)

miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease
por: Li, Shuangshuang, et al.
Publicado: (2016)

Aggravated pulmonary injury after subarachnoid hemorrhage in PDGF-B(ret/ret) mice
por: Pan, Pengyu, et al.
Publicado: (2020)

Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_50ktllp2jcbiec1aiadbvdov9k